Previous genetic discoveries in AAA have pointed to inflammation and immune function (IL6R and CDKN2BAS1/ANRIL) and low-density lipoprotein metabolism (SORT1 and LDLR) as important mediators of AAA development. This evidence concerns the gene CDKN2B-AS1 and triple-A syndrome.